A population-based bayesian pharmacokinetic modelling of [ 177 Lu]Lu-PSMA-617 for whole-body single-time-point dosimetry (EANM 2026) - Sep 29, 2026 - Abstract #OP-112; Pres time: Oct 18, 2026; 09:45 AM - 11:15 AM; Location: Hall F1; "Bayesian pharmacokinetic modelling allows for whole-body single-time-point dosimetry in Lu177-PSMA-617 therapy, with day-1 sampling offering the best balance of accuracy and clinical feasibility."
Clinical • PK/PD data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Prostate Cancer • Solid Tumor
|
|
A. Terro 1; T. Zaragori 2, 3; C. Boursier 4; P. Vera 1, 5; P. Decazes 1, 5; L. Imbert 3, 4; T. Dufflot 6; A. Dieudonné 1, 5
|